ELISA/assay

Human Apolipoprotein A2 ELISA Kit

MBS720600

48-Strip-Wells-(Comp

470 USD

ELISA Kit

Human Apolipoprotein A2 ELISA Kit

Apolipoprotein A2

apolipoprotein A-II preproprotein; Apolipoprotein A-II; apolipoprotein A-II; apolipoprotein A2; apolipoprotein A-II; Apolipoprotein A2Cleaved into the following 2 chains:Proapolipoprotein A-II; ProapoA-II; Truncated apolipoprotein A-IIAlternative name(s):Apolipoprotein A-II(1-76)

APOA2

APOA2; APOA2; apoAII; Apo-AII; ApoA-II; Apo-AII; ApoA-II; ProapoA-II

APOA2_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of ApoA2. No significant cross-reactivity or interference between ApoA2 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between ApoA2 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Assay Type: Competitive or Sandwich. Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Sensitivity: 1.0 mg/L.

Intended Uses: This ApoA2 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human ApoA2. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cardiovascular

Principle of the assay: ApoA2 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti- ApoA2 antibody and an ApoA2-HRP conjugate.The assay sample and buffer are incubated together with ApoA2-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the ApoA2 concentration since ApoA2 from samples and ApoA2-HRP conjugate compete for the anti-ApoA2 antibody binding site. Since the number of sites is limited, as more sites are occupied by ApoA2 from the sample, fewer sites are left to bind ApoA2-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The ApoA2 concentration in each sample is interpolated from this standard curve.

4502149

NP_001634.1

NM_001643.1

11,175 Da

Chylomicron-mediated Lipid Transport Pathway (106157); Complement And Coagulation Cascades Pathway (198880); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Pathway (477135); Metabolism Of Lipids And Lipoproteins Pathway (160976); PPAR Signaling Pathway (83042)

This gene encodes apolipoprotein (apo-) A-II, which is the second most abundant protein of the high density lipoprotein particles. The protein is found in plasma as a monomer, homodimer, or heterodimer with apolipoprotein D. Defects in this gene may result in apolipoprotein A-II deficiency or hypercholesterolemia. [provided by RefSeq, Jul 2008]

APOA2: May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. Belongs to the apolipoprotein A2 family. Protein type: Lipid-binding; Endoplasmic reticulum; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 1q23.3. Cellular Component: chylomicron; endoplasmic reticulum lumen; early endosome; extracellular region; cytosol. Molecular Function: lipid transporter activity; protein binding; protein homodimerization activity; lipase inhibitor activity; protein heterodimerization activity; cholesterol transporter activity; cholesterol binding; phospholipid binding; phosphatidylcholine binding; lipid binding; high-density lipoprotein binding; apolipoprotein receptor binding. Biological Process: positive regulation of catalytic activity; phototransduction, visible light; protein folding; viral reproduction; negative regulation of cholesterol transport; response to glucocorticoid stimulus; regulation of protein stability; diacylglycerol catabolic process; positive regulation of lipid catabolic process; cellular lipid metabolic process; negative regulation of lipase activity; negative regulation of lipid catabolic process; regulation of cholesterol absorption; phospholipid efflux; response to glucose stimulus; retinoid metabolic process; response to drug; cholesterol metabolic process; organ regeneration; protein amino acid oxidation; phospholipid catabolic process; positive regulation of interleukin-8 biosynthetic process; lipoprotein metabolic process; cholesterol efflux; negative regulation of cytokine secretion during immune response; cholesterol homeostasis; reverse cholesterol transport; triacylglycerol metabolic process; response to estrogen stimulus; peptidyl-methionine modification; phosphatidylcholine biosynthetic process; acute inflammatory response. Disease: Hypercholesterolemia, Familial

48-Strip-Wells-(Competitive)

470 USD

48-Strip-Wells-(Sandwich)

470

96-Strip-Wells-(Competitive)

675

96-Strip-Wells-(Sandwich)

675